Sandu Pharmaceuticals Ltd (524703)

Sandu Pharmaceuticals Limited has issued intimations to physical shareholders to submit their PAN, KYC details, and bank credentials to its Registrar and Transfer Agent (MUFG Intime India Pvt Ltd) as mandated by SEBI. In line with regulatory rules, failure to update bank details means any declared dividend or interest will only be processed electronically upon submission of complete records. The notice also highlights a special window available until February 04, 2027, for the re-lodgement of transfer deeds rejected prior to April 01, 2019.

• Reminder letters dispatched to physical share holders on September 29, 2026
• Special window for re-lodgement of transfer deeds open from February 05, 2026 till February 04, 2027
• SEBI Master Circular reference dated June 23, 2025 and circular dated February 06, 2026 mandated the compliance
• Addresses re-lodgements rejected prior to the deadline of April 01, 2019

Sandu Pharmaceuticals has dispatched physical letters providing the weblink to its Annual Report to shareholders whose email addresses are not registered with the company or RTA. The company's 41st Annual General Meeting is scheduled to be held virtually on September 11, 2026, at 4:30 PM. The filing is a routine administrative compliance step under Regulation 36(1)(b) of SEBI LODR Regulations with no impact on operations or financials.

• 41st Annual General Meeting scheduled for September 11, 2026, at 4:30 PM via video conference
• Letters sent to unregistered shareholders based on the cut-off date of August 7, 2026
• Compliance intimation under Regulation 36(1)(b) of SEBI LODR Regulations, 2015

Sandu Pharmaceuticals Limited has released its 41st Annual Report along with the notice for its 41st Annual General Meeting scheduled for September 11, 2026. For FY26, the company reported revenue from operations of ₹6,993.45 lakhs (₹69.93 Cr), up from ₹6,719.24 lakhs in FY25. Net profit increased by 23.187% year-on-year, driven by cost management and operational efficiencies despite higher business promotion expenses of ₹924.59 lakhs.

• Annual General Meeting (AGM) scheduled for Friday, 11th September 2026 via VC/OAVM
• Revenue from operations reached ₹6,993.45 lakhs in FY26 versus ₹6,719.24 lakhs in FY25
• Net profit recorded an increase of 23.187% year-on-year
• Business promotion expenses rose to ₹924.59 lakhs from ₹699.21 lakhs in the previous year

Sandu Pharmaceuticals has issued the notice for its 41st Annual General Meeting scheduled for September 11, 2026. The agenda includes shareholder approval for a dividend of ₹1.00 per share (10% on face value of ₹10) for FY26. Additionally, the company seeks approval for material related-party transactions with Sandu Brothers Private Limited up to ₹100 crore, alongside the appointment of M/s. Dave & Dave as statutory auditors for a 5-year tenure.

• 41st Annual General Meeting scheduled for Friday, September 11, 2026 at 4:30 PM via VC/OAVM
• Proposed dividend declaration of ₹1.00 per share (10% on ₹10 face value) for FY26
• Approval sought for material related-party transactions with Sandu Brothers Private Limited up to ₹100 crore
• Appointment of M/s Dave & Dave, Chartered Accountants, as statutory auditors for a 5-year term ending at the 46th AGM in 2031
• Ratification of Cost Auditor remuneration of ₹1,30,000 per annum for FY 2026-27

Sandu Pharmaceuticals reported a flat year-on-year performance for Q1 FY27, with revenue from operations at Rs 16.39 Cr compared to Rs 16.70 Cr in the previous year. Net profit remained stable at Rs 0.23 Cr, while EPS improved slightly to Rs 0.37 from Rs 0.23 YoY. The board has recommended the continuation of material related party transactions with Sandu Brothers Private Limited, pending shareholder approval at the AGM on September 11, 2026. A record date of September 4, 2026, has been set for the FY26 dividend eligibility.

• Revenue from operations for Q1 FY27 stood at Rs 16.39 Cr, a marginal decline of 1.8% compared to Rs 16.70 Cr in Q1 FY26.
• Net profit for the quarter was Rs 0.23 Cr, showing minimal change from the Rs 0.22 Cr reported in the same period last year.
• Record date for the FY26 dividend is fixed for September 4, 2026, with the AGM scheduled for September 11, 2026.
• Proposed appointment of M/s. Dave & Dave as Statutory Auditors for a 5-year term starting from the conclusion of the upcoming AGM.
• Board recommended shareholder approval for material related party transactions with M/s. Sandu Brothers Private Limited.

Sandu Pharmaceuticals has filed its quarterly statement of deviation for the period ended June 30, 2026, confirming that funds raised through preferential issues between 2021 and 2022 are being used as intended. The company raised a total of approximately Rs 5.34 Cr across three tranches to fund plant revamping, marketing infrastructure, and working capital. While the first two tranches are fully utilized, the third tranche of Rs 1.32 Cr remains partially unutilized and is currently held in a Fixed Deposit with Bank of Baroda. This is a routine regulatory disclosure with no reported deviations or changes in objects.

• Total funds raised across three preferential tranches between March 2021 and July 2022 amount to Rs 5.34 Cr.
• Tranche 1 raised Rs 2.64 Cr on March 31, 2021, for revamping capital and marketing infrastructure.
• Tranche 2 raised Rs 1.38 Cr on February 28, 2022, via warrant conversion at Rs 20.69 per share.
• Tranche 3 raised Rs 1.32 Cr on July 14, 2022, with Rs 46.56 lakh utilized as of the reporting date.
• Unutilized proceeds are currently maintained in a Fixed Deposit with Bank of Baroda.

Sandu Pharmaceuticals reported a flat Q1 FY27 with revenue of Rs 16.39 Cr, a marginal 1.8% decline from Rs 16.70 Cr in the same quarter last year. Net profit remained stable at Rs 0.23 Cr, matching the previous year's performance. The board has recommended the appointment of M/s Dave & Dave as statutory auditors for a five-year term (FY27-FY31). Additionally, the company set September 4, 2026, as the record date for the FY26 dividend and is seeking shareholder approval for material related-party transactions with Sandu Brothers Private Limited.

• Q1 FY27 Revenue reported at Rs 16.39 Cr, down 1.8% from Rs 16.70 Cr YoY
• Net Profit for the quarter ended June 2026 stood at Rs 0.23 Cr, identical to Q1 FY26
• Appointment of M/s Dave & Dave as Statutory Auditors for a 5-year term starting FY27
• Record date for FY26 dividend eligibility set for September 4, 2026
• Total expenses for the quarter were Rs 16.05 Cr, slightly lower than Rs 16.38 Cr in the year-ago period

Sandu Pharmaceuticals reported a flat performance for Q1 FY27, with a net profit of ₹0.23 Cr, nearly identical to the ₹0.22 Cr reported in the same quarter last year. Revenue from operations declined marginally by 1.8% YoY to ₹16.39 Cr. The company has fixed September 4, 2026, as the record date for its FY26 dividend. Additionally, the board has proposed the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term and is seeking approval for material related-party transactions.

• Revenue from operations for Q1 FY27 stood at ₹16.39 Cr, compared to ₹16.70 Cr in Q1 FY26.
• Net profit for the quarter remained stagnant at ₹0.23 Cr (₹22.84 lakhs).
• Record date for the FY26 dividend is fixed for September 4, 2026, with the AGM scheduled for September 11, 2026.
• Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term until 2031.
• Total expenses for the quarter were ₹16.05 Cr, accounting for 97.8% of total income.

Sandu Pharmaceuticals has scheduled a board meeting for August 11, 2026, to consider and approve the standalone unaudited financial results for the quarter ended June 30, 2026. This is a routine regulatory filing for a micro-cap company with a market capitalization of Rs 38 Cr. In the previous year's corresponding quarter (June 2024), the company reported a revenue of Rs 17.05 Cr and a net profit of Rs 0.17 Cr. Investors will be monitoring if the company can improve its thin operating margins, which stood at 4.1% for FY25.

• Board meeting to be held on August 11, 2026, at 04:00 p.m. in Mumbai.
• Financial results to be reviewed for the quarter ended June 30, 2026.
• Trading window has been closed since July 1, 2026, for directors and designated employees.
• Company reported TTM revenue of Rs 67 Cr and TTM PAT of Rs 2 Cr.
• Promoter holding remained stable at 37.79% as of June 2026.